Disitamab Vedotin Combined With Platinum and Bevacizumab as First-Line and Maintenance Therapy for HER2-Expressing, HRD-Negative High-Risk Ovarian Cancer: A Multicenter, Non-Randomized, Single-Arm Phase II Clinical Study

NCT07311577 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

43

Enrollment

OTHER

Sponsor class

Conditions

Ovarian Cancer Metastatic
Ovarian Cancer Metastatic Recurrent

Interventions

DRUG: RC48+Carboplatin+Bevacizumab

Sponsor

Jiangsu Cancer Institute & Hospital